Methylation Changes at the IGF2-H19 Locus in Growth Disorders and Cancer
Author Information
Author(s): Murrell Adele, Ito Yoko, Verde Gaetano, Huddleston Joanna, Woodfine Kathryn, Silengo Margherita Cirillo, Spreafico Filippo, Perotti Daniela, De Crescenzo Agostina, Sparago Angela, Cerrato Flavia, Riccio Andrea
Primary Institution: Department of Oncology, University of Cambridge
Hypothesis
How do methylation changes at the IGF2 DMR0 region contribute to congenital growth disorders and cancer?
Conclusion
The study found that methylation changes at the IGF2 DMR0 region are linked to different mechanisms in congenital growth disorders and Wilms tumor.
Supporting Evidence
- Patients with Beckwith-Wiedemann syndrome showed hypermethylation at DMR0.
- SRS patients with IC1 hypomethylation also had hypomethylation at DMR0.
- Wilms tumor patients with hypermethylation at IC1 had reduced methylation at DMR0.
Takeaway
This study looked at how certain genes are turned on or off in kids with growth disorders and cancer, finding that the way these genes are controlled can be different in sick kids compared to healthy ones.
Methodology
The researchers analyzed the methylation status of the DMR0 in patients using bisulphite sequencing and pyrosequencing.
Limitations
The study may not account for all genetic and environmental factors influencing methylation changes.
Participant Demographics
Participants included 85 BWS patients and 3 SRS patients from various Italian Pediatric Departments.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website